Silence at Takeda and Nycomed, but a desire to expand
This article was originally published in Scrip
Executive Summary
Takeda and Nycomed have both refused to comment on the rumoured acquisition discussions. Japan's largest drug firm is said to be considering paying up to $14 billion for the Swiss pharma company, whose largest shareholder is Nordic Capital with around a 42% stake. However, advisors close to the companies have indicated that there is substance to the rumour.